AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in Chinanews2025-03-21T15:24:18+00:00March 21st, 2025|Endpoints News|
AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneronnews2025-03-21T15:17:54+00:00March 21st, 2025|Endpoints News|
Visen Pharmaceuticals prices $86M Hong Kong IPOnews2025-03-20T16:40:24+00:00March 20th, 2025|Endpoints News|
WuXi AppTec’s US revenue growth continues to dip in post-Biosecure environmentnews2025-03-17T18:34:26+00:00March 17th, 2025|Endpoints News|
Merck KGaA says earlier moves to localize manufacturing help ease Trump tariff impact news2025-03-06T15:26:35+00:00March 6th, 2025|Endpoints News|
China bans imports of Illumina’s DNA sequencers following US tariffsnews2025-03-04T20:24:53+00:00March 4th, 2025|Endpoints News|
Chinese ADC biotech lets Hong Kong IPO filing lapsenews2025-02-25T17:31:04+00:00February 25th, 2025|Endpoints News|
Pfizer wants in on Summit’s goal to beat Keytruda via ADC combosnews2025-02-24T12:18:40+00:00February 24th, 2025|Endpoints News|
How Keymed steered the China-to-US NewCo model in biotechnews2025-02-20T16:20:44+00:00February 20th, 2025|Endpoints News|
AstraZeneca buys FibroGen’s China unit for local control of anemia drugnews2025-02-20T12:35:47+00:00February 20th, 2025|Endpoints News|
